Isolation of α_1 -Protease Inhibitor from Human Normal and Malignant Ovarian Tissue

A. BAGDASARIAN, J. WHEELER, G. J. STEWART, S. S. AHMED, and R. W. COLMAN,
*Specialized Center for Thrombosis Research, Temple University Health Sciences
Center; Departments of Medicine and Pathology, University of Pennsylvania
School of Medicine, Philadelphia, Pennsylvania 19140*

ABSTRACT Proteolytic enzymes are associated with normal and neoplastic tissues. Therefore protease inhibitors might also be involved in the control of cell function. α_1 -protease antigen and antitryptic activity have been found in normal and neoplastic human ovarian homogenate. The inhibitor has been localized to ovarian stromal cells or tumor cells by immunoperoxidase staining. The protein was purified to apparent homogeneity as judged by alkaline gel and sodium dodecyl sulfate (SDS) gel electrophoresis. Immunochemical studies revealed antigenic similarity to plasma α_1 -protease inhibitor by double immunodiffusion and similar mobility on immunoelectrophoresis and two-dimensional electroimmunodiffusion. The molecular weight was similar to that described for plasma α_1 -protease inhibitor: 60,000 by gel filtration and 53,500 by SDS electrophoresis. Furthermore, the phenotypic pattern as determined by acid starch gel electrophoresis and immunoprecipitation was PiMM, which is the predominant genetic variant in normal plasma α_1 -protease inhibitor. An inhibitor was isolated and purified from an ovarian carcinoma that exhibited functional, immunochemical, and physical similarity to the normal ovarian α_1 -protease inhibitor. α_1 -protease inhibitor from normal and malignant ovaries competitively inhibited bovine pancreatic trypsin at incubation times of 5 min at 30°C. Inhibition constant (K_i) values were calculated at 0.67 and 0.51 inhibitory units, respectively. The α_1 -protease inhibitor in malignant cells may be a factor in the control of proliferation in this tissue. Since ovulation is in part a proteolytic event, the α_1 -protease inhibitor in ovarian cells may play a role in the control of this specialized tissue. Persistence of this protein in malignant ovarian tissue may be a vestige of its differentiated origin.

INTRODUCTION

α_1 -Protease inhibitor (α_1 -antitrypsin) is a glycoprotein that probably functions as the major inhibitor of tissue proteases including trypsin (1), chymotrypsin (1), elastase (2), collagenase (3), and renin (4). The importance of α_1 -protease inhibitor in human disease is indicated by the observation that its deficiency is associated with pulmonary emphysema (5, 6) and liver disease (7, 8). Direct and indirect evidence suggests that the liver is the site of synthesis of the plasma α_1 -protease inhibitor (9–12). However, the action of this inhibitor is directed primarily toward tissue rather than plasma proteolytic enzymes, suggesting that it might also be synthesized in cells and tissue aside from the liver. The occurrence of α_1 -protease inhibitor in extrahepatic sites may be important, since certain protease inhibitors inhibit the growth of tumor cells (13, 14) or the process of transformation (15). Thus, the increased level of protease activity in malignant cells (16, 17) might be due to a deficiency of protease inhibitors in these cells. In addition, the role of proteolysis in such physiological events as ovulation (18), suggests that inhibitory function might exist for tissue α_1 -protease inhibitor, were it present.

In this study ovarian tissue was selected for detailed examination for three reasons. The ovary with its hormonally controlled cyclic proliferation and involution represents a tissue capable of high levels and diversified types of protein synthesis. Malignant and normal tissue can be obtained in reasonable amounts for protein isolation. A discrete physiological function, that of ovulation, is known to be associated with proteolytic activity involving trypsin-like enzymes (18). This study demonstrates that ovarian stromal cells contain α_1 -protease inhibitor and that the major trypsin inhibitory activity of ovarian tissue is due to this inhibitor. The α_1 -protease inhibitor has been purified and characterized from normal and malignant cells and this appears to be conserved in neoplastic cells.

Dr. Bagdasarian's current address is Hyland Laboratories, Therapeutic Division, Glendale, Calif.

Received for publication 16 July 1980 and in revised form 17 September 1980.

Finally, the occurrence of this inhibitor in the ovary invites future exploration of its role in ovulation.

METHODS

Ovary procurement. Three normal, one polycystic, and five malignant ovaries were obtained from nine patients during surgery. A representative portion was removed and fixed in Bouin's solution, dehydrated, and embedded in paraffin blocks. Sections from all nine were used for hematoxylin and eosin staining and for immunoperoxidase studies for α_1 -protease inhibitor (see below). Three ovaries were selected for in depth study of the α_1 -protease inhibitor. One was a normal postmenopausal ovary without follicles (B.L.), the second a polycystic ovary with multiple follicles (A.S.), and the third was a mucinous cystadenocarcinoma containing no follicles (G.B.). These were used for preparation of tissue homogenates for isolation of α_1 -protease inhibitors.

Immunocytochemical techniques. Immunoperoxidase reactions for α_1 -antitrypsin were tested on unstained, deparaffinized, and hydrated 6 μ m sections, by using commercially available reagents (see "Antisera") and brief rinses with 0.1 M sodium phosphate buffer pH 7.4 containing 0.15 M NaCl (PBS)¹ between steps, in a three-layered immunoenzyme bridge technique with unlabeled antibody and soluble peroxidase-antiperoxidase complex (19). The technique involved slide incubation in a moist chamber, and the following timed application sequence: (a) 1:40 rabbit anti-human α_1 -antitrypsin, prepared by diluting the antiserum 1:20 with PBS, then adding an equal volume of undiluted normal goat serum, 30 min; (b) undiluted normal goat serum, 15 min; (c) 1:50 goat anti-rabbit IgG, using a 1:25 dilution with PBS, then addition of an equal volume of 1:10 normal goat serum diluted with PBS, 30 min; (d) 1:50 peroxidase-antiperoxidase complex, diluted 1:25 with PBS, then 1:10 normal goat serum, 30 min; (e) 3,3'-diaminobenzidine/hydrogen peroxide solution, prepared immediately before use, by dissolving 5 mg of diaminobenzidine in 10 ml of 0.05 M Tris HCl buffer, pH 7.2, then adding four to five drops of 3% H₂O₂, 5–10 min; followed by counterstaining, dehydration, permanent mounting, and examination by light microscopy (20).

The specificity of the primary antiserum was tested before use by double diffusion (21). For control, primary antiserum was replaced with normal rabbit serum, PBS, or absorbed primary antiserum.

Chemicals. Acrylamide, *N,N'*-methylene-bis-acrylamide, *N,N,N',N'*-tetramethylene diamine were obtained from Bio-Rad Laboratories, Richmond, Calif. Coomassie blue was obtained from Ames Co., Div. of Miles Laboratories, Elkhart, Ind. Ammonium persulfate was purchased from Fisher Scientific Co., Pittsburgh, Pa. Agarose from Litex Co., Copenhagen, Denmark. Plates containing 1% agarose for double diffusion were obtained from Hyland Diagnostics Div. Travenol Laboratories, Costa Mesa, Calif. Hexadimethrene bromide (polybrene) was obtained from Abbott Laboratories, North Chicago, Ill. Dithiothreitol, dextran blue and 3,3'-diaminobenzidine were from Sigma Chemical Co., St. Louis, Mo. Sodium dodecyl sulfate was obtained from Schwartz/Mann Div., Becton, Dickinson & Co., Orangeburg, N. Y. QAE-Sephadex, Sephadex G-200, Sepharose-4B, concanavalin A (Con A)-Sepharose and Blue Dextran 2000 were obtained from Pharmacia Fine Chemicals, Div. Pharmacia Inc., Piscataway, N. J. Preswollen DEAE-cellulose was purchased from Whatman Inc., Clifton, N. J. All other chemicals were reagent grade.

¹ Abbreviation used in this paper: PBS, 0.1 M phosphate-buffered saline (pH 7.4) containing 0.15 M NaCl.

Molecular weight standards. For the calibration of gel filtration columns the following standards were obtained from Sigman Chemical Co.: twice crystallized bovine serum albumin, α -chymotrypsinogen (bovine pancreas, type II, six times crystallized), ovalbumin (crystallized and salt free), and human γ -globulin.

Substrates. Benzoyl-L-phenylalanyl-L-valyl-L-arginyl-p-nitroanilide (Bz-Phe-Val-Arg-pNA) was purchased from Kabi Peptide Research Molndal, Sweden. Bz-Phe-Val-Arg-pNA was dissolved in distilled water, either by stirring for 1 h or by sonication for four periods of 14 s each to yield a 1 mM solution. H-D-phenylalanyl-L-valyl-L-arginyl-p-nitroanilide (H-D-Val-Leu-Lys-pNA) was purchased from Ortho Diagnostics, Raritan, N. J., and 3 mM solution was prepared in distilled water. H-D-Glu-Gly-Arg-pNA was a gift from Kabi Peptide Research Molndal, Sweden. Para-nitrophenyl-p-guanidinobenzoate HCl was purchased from Vega Fox Biochemicals, Div. Newbery Energy Tucson, Ariz. α -Casein was obtained from Fisher Scientific Co. Benzamidine hydrochloride hydrate was purchased from Aldrich Chemical Co., Inc., Milwaukee, Wisc.

Enzymes. Bovine pancreatic trypsin (crystallized three times) treated with tosylphenylalanylchloromethyl ketone to render it free of chymotryptic activity was obtained from Worthington Biochemical Corp., Freehold, N. J. Plasminogen was prepared by affinity chromatography (22) or was purchased from Kabi, Stockholm, Sweden. Both preparations of plasminogen gave similar results. Varidase (Lederle Laboratories, Div. American Cyanamid Co., Pearl River, N. Y.) was the source of streptokinase. Human plasma kallikrein was prepared in our laboratory by alcohol and salt fractionation and ion exchange chromatography and was further purified by gel filtration (23). Urokinase was obtained from Calbiochem-Behring Corp., American Hoechst Corp., San Diego, Calif.

Antisera. Antibodies prepared in rabbits against human plasma proteins, anti- α_1 -antitrypsin, anti-inter- α -trypsin inhibitor, anti- α_2 -macroglobulin, anti-Cl inhibitor, anti-thrombin III, anti-transferrin, and anti-haptoglobin were obtained from Behring Diagnostics, Somerville, N. J. Anti- α_2 plasmin inhibitor was a gift from Dr. Aoki of Jichi Medical School, Japan. Peroxidase conjugated to anti-rabbit gamma globulin and goat anti-rabbit IgG were purchased from N. L. Cappel Laboratories, Cochranville, Pa.

Column chromatography and gel filtration. QAE and G-200 Sephadex and DEAE-cellulose were equilibrated with the starting buffer according to the directions of the manufacturer, and were packed into columns by gravity. A standard curve was constructed to estimate molecular weights by gel filtration. The following proteins were used: human γ -globulin, bovine serum albumin, ovalbumin, and α -chymotrypsinogen. Sephadex G-200 filtration was carried out using a downward flow column (1.6 $\times$ 86.5 cm) at a constant operating pressure of 40 cm. Samples of up to 2% of the column volume were applied. The flow rate was 8 ml/h.

Affinity chromatography. To remove albumin from purified inhibitor, a Con A-Sepharose column was used. A small column (2 ml vol) was packed and equilibrated with 0.01 M acetate buffer at pH 6.5 containing 0.2 M NaCl, 1 mM of each CaCl₂ and MnCl₂. Inhibitor samples containing <10 mg total protein were passed through the resin at 4°C. After the removal of the unabsorbed proteins by the starting buffer, the inhibitor was eluted from the Con A-Sepharose with a 0.1-M solution of α -methyl-D-glucoside in the 0.05 M Tris buffer. 1-ml fractions were collected and assayed for trypsin inhibition. For functional studies, fractions containing the inhibitor were pooled and stabilized with bovine serum albumin 100 μ g/ml before concentration. The recovery of inhibitor is generally ~75% based on the total trypsin inhibitory capacity of the material applied to the column.

Gel electrophoresis. Analytical polyacrylamide disc gel electrophoresis was performed according to Davis (24). Samples in 4% sucrose were applied to 7% polyacrylamide gels, and electrophoresis was carried out for 2 h at 4°C, 2.5 mA per gel. To locate protein bands, gels were stained for 3 h with 0.1% Coomassie blue. Polyacrylamide gel electrophoresis in sodium dodecyl sulfate was performed according to Weber and Osborn (25). A standard curve for the calibration of the molecular weights was constructed using the molecular weight markers for sodium dodecyl sulfate gel electrophoresis, obtained from BDH Chemicals Ltd., Poole, England.

Tissue homogenization and subcellular fractionation. Tissues were obtained from surgery and carefully washed free of any adhering blood clots and frozen immediately if not processed right away. All operations were carried out at 4°C. Each 10 g of fresh or frozen tissue was cut in small pieces (~3 mm thick) and rinsed with 150 ml ice-cold solution of 0.25 M sucrose in 0.01 M Tris-Cl buffer pH 7.4 containing 1 mM EDTA, azide, benzamide, and 50 µg per ml hexadimethrine. Rinsing was repeated three times for 30 min. Tissue slices were then placed on a stainless steel sieve (40 mesh) and rinsed once more with 50 ml of the above buffer. The rinsed tissue was then pressed through the sieve and taken up in the same buffer (6 ml/g tissue) and homogenized in small aliquots using an all-glass loose-fitting homogenizer of Dounce type. The final homogenate was taken up in a total of 10 ml buffer/g tissue. Subcellular fractions were then prepared by the general method of differential centrifugation (26). Lysosomes were further purified from the light mitochondria by sucrose density gradient centrifugation (27). To solubilize lysosomal contents, deoxycholate solution at final concentration of 0.5% was added to the suspended lysosomes in 0.0035 M phosphate buffer, containing 0.06 M NaCl, pH 8.0, and incubated at 0°C for 30 min before centrifugation for 30 min at 12,000 g to obtain clear supernate.

Ammonium sulfate precipitation. Saturated ammonium sulfate solution adjusted to pH 7.0 by the addition of 1 M NaOH solution, was added to the 100,000 g supernate from rinsed homogenized tissue or solubilized lysosomal contents at 0°C with constant stirring. After 45 min the precipitate was collected by centrifugation at 3,000 g at 4°C for 30 min and redissolved in the 0.01 M Tris-HCl buffer, pH 8.0. Samples were dialyzed against 0.05 M Tris buffer, pH 8.0, overnight.

Immunological analysis. Double-immunodiffusion was performed by the method of Ouchterlony (21) using 1% agarose plates. Radial immunodiffusion was performed by a minor modification of the method of Mancini et al. (28) with a final concentration of 1% agarose in barbital buffer, pH 7.6, 1:36 dilution of antiserum, and 0.01% merthiolate. Immunelectrophoresis was performed by the method of Scheidigger (29), using 1% agarose plates. Crossed immunelectrophoresis was carried out according to Laurell (30) with minor modifications. α -protease inhibitor phenotyping was carried out according to Fagerhol and Laurell (31).

Preparation of immobilized trypsin. Sepharose-4B was activated by cyanogen bromide and coupled to bovine trypsin by the method of Cuatrecasas (32) as previously described (33). Trypsin (100 mg) in 25 ml of 0.1 M sodium bicarbonate, pH 8.9, was added to the activated agarose slurry containing 40 ml resin and 25 ml of the above buffer. The concentration of active trypsin in solution or bound to agarose was determined by the active site titration method of Chase and Shaw (34). Approximately 1 mg trypsin was linked to each milliliter of resin.

Inhibition of trypsin amidase activity. Inhibition by cell components was determined by measuring the degree of hydrolysis using a tripeptide *p*-nitroanilide substrate. Up to 0.30 ml of sample from different stages of purification was mixed with 0.05 M Tris imidazole buffer, pH 8.1, containing 0.1 M

NaCl and 0.5 mg/ml bovine serum albumin (in a total volume of 0.9 ml), and 0.01 ml of trypsin (0.3 µg). The mixture was incubated at 30°C for 5 min unless otherwise stated. At the end of the incubation period, 0.1 ml of 1 mM substrate Bz-Pro-Val-Arg-*p*NA was added and incubated for 2 min. The reaction was stopped by the addition of 0.1 ml glacial acetic acid and the color formed measured at 405 nm with a Gilford 240 spectrophotometer (Gilford Instrument Laboratories, Inc., Oberlin, Ohio). The blanks did not contain trypsin and the control contained buffer instead of sample.

Inhibition of trypsin proteolytic activity. A mixture of up to 0.3 ml 0.1 M phosphate buffer at pH 7.65, 0.01 ml trypsin (0.3 µg), and bovine serum albumin at a final concentration of 0.5 mg/ml was incubated for 4 min at 30°C. The degree of hydrolysis of casein and the extent of the inhibition were determined according to the method of Alkjaersig et al. (35).

Inhibitor units. Hydrolysis of Bz-Pro-Val-Arg-*p*NA and H-D-Val-Leu-Lys-*p*NA was linear for at least 3 min under the experimental conditions. In the trypsin or plasmin amidase assays, when the remaining enzymes' activity was plotted on a semilog graph against the concentration of the inhibitor, a linear relationship was obtained. Therefore, we arbitrarily chose 1 U of inhibitor to be equal to that amount that could inhibit 50% of trypsin (0.30 µg) or plasmin (0.05 casein units) activity.

Inhibition of plasmin amidase activity. The tripeptide substrate, H-D-Val-Leu-Lys-*p*NA was used. Up to 0.3 ml of inhibitor source was mixed with 0.05 M Tris-Cl buffer at pH 7.4, containing 1 mg/ml bovine serum albumin in a total volume of 0.9 ml; and 0.01 ml of plasmin (0.05 casein units). After incubation of the mixture for 5 min, 0.1 ml of the substrate (3 mM) was added and further incubated for 3 min. The reaction was stopped by the addition of 0.1 ml of 50% glacial acetic acid and the color formed measured at 405 nm. The blanks did not contain plasmin and the controls contained buffer instead of sample.

Affinity chromatography of trypsin inhibitors. To selectively isolate trypsin inhibitors, soluble fraction or lysosomal content from various tissues were exposed to trypsin-sepharose columns (36), equilibrated with 0.05 M Tris-Cl buffer, pH 7.4 containing 0.13 M NaCl, at 4°C. The resin was further washed with 0.3 M NaCl, 0.02 M CaCl₂ solution (twice the column volume) and the trypsin inhibitors were eluted with 0.02 M HCl containing 0.3 M NaCl, 0.02 M CaCl₂.

Determination of protein concentration. Fractions obtained from chromatography were examined for their absorption at 280 nm. For a more sensitive estimation of the protein concentration, the micro-Folin-Ciocalteu method was used. The specific activities of inhibitors were expressed as units per milligram protein.

Concentration of protein samples. Fractions containing various inhibitory activities were pooled and concentrated in an Amicon ultrafiltration device (Amicon Corp., Scientific Sys. Div., Lexington, Mass.) using a YM-10 membrane.

RESULTS

Demonstration of α_1 -protease inhibitor in ovaries by the indirect peroxidase reaction. The presence of α_1 -protease inhibitor antigen in formalin-fixed paraffin sections of nine freshly removed ovaries was shown by the use of specific α_1 -protease inhibitor antibody and a binding antibody conjugated to peroxidase. In normal ovaries the reaction product (representing antigen) was intense in the germinal epithelium covering the

FIGURE 1 Immunocytochemical localization of α_1 -antitrypsin in ovaries by indirect peroxidase-antiperoxidase procedure. All frames are light micrographs. Frame A establishes the specificity of the antibody and peroxidase reaction by showing the absence of reaction product when normal rabbit serum was substituted for specific antibody in the primary step. This was used as a control for all ovaries examined. Note the absence of reaction product from stromal cells whereas faint reaction product is present in vessels indicating the presence of endogenous peroxidase in the blood cells, $\times 400$. Frames B-F show the distribution of dense (dark) reaction product which corresponds to distribution of α_1 -antitrypsin antigen when specific α_1 -antitrypsin antibody was used in

ovary and specially in the stromal cells of the cortex (Fig. 1). In contrast, the follicular cells and the interstitial space were essentially free of reaction product. Samples that were not exposed to the specific antibody for α_1 -protease inhibitor before exposure to the peroxidase conjugate and substrate showed no reaction product in ovarian cells or interstitial space, but the cell-filled blood vessels developed a faint reaction product with the substrate alone, indicating the presence of endogenous peroxidase in the blood cells. This has been demonstrated for the granules of granulocytes as well as for hemoproteins (20). In the malignant tissue the reaction product was more dense but very irregularly distributed in the stroma and confined to only some of the stromal cells but most of the tumor cells. All corpora lutea were completely devoid of reaction product or were barely visible. Nine ovaries, (three normal, one polycystic, and five malignant) from nine patients, all showed the same pattern of distribution of α_1 -protease inhibitor antigen.

Identification of α_1 -protease inhibitor in ovarian homogenate subfractions by immunochemical characteristics and inhibitor activity. Subcellular fractions of a normal ovary (B.L.), a polycystic ovary (A.S.), and an adenocarcinoma of ovary (G.B.) were prepared as described in Methods. In the nonmalignant ovary (A.S.) (Fig. 2a) the antigen detected, α_1 -protease inhibitor, was found in the homogenate (not shown) and soluble fraction (well 3). The Triton-solubilized membrane fraction showed a faint line (well 4). Both cell fractions demonstrated complete identity with plasma α_1 -protease inhibitor (wells 2, 5). The concentration of α_1 -protease inhibitor in the soluble fractions of normal ovary (B.L.) and polycystic ovary (A.S.) were 30 and 9 $\mu\text{g}/\text{mg}$ protein, respectively, using radial immunodiffusion.

The ovarian carcinoma (G.B.) (Fig. 2b) soluble fraction (well 1) showed complete identity with plasma α_1 -protease inhibitor (well 2). The membrane fraction solubilized in Triton (well 3) also showed a line of identity with plasma α_1 -protease inhibitor (wells 2 and 4). Solubilization of the membrane in deoxycholate (well 5) completely interfered with the antigen antibody reaction. The soluble fraction from normal ovary tested by radial immunodiffusion showed small amounts

of α_1 -antichymotrypsin (5.9 $\mu\text{g}/\text{mg}$ protein) and inter- α -antitrypsin (3 $\mu\text{g}/\text{mg}$ protein). Soluble and lysosomal fractions from carcinoma (G.B.) also showed the presence of small amounts of inter- α -antitrypsin. The concentration of α_1 -protease inhibitor in the soluble fraction was assayed at 18 $\mu\text{g}/\text{mg}$ protein using radial immunodiffusion.

To study the electrophoretic mobilities of α_1 -protease inhibitor from various sources, soluble fractions from normal ovary (A.S.) and ovarian carcinoma (G.B.) were compared to plasma α_1 -protease inhibitor by immunoelectrophoresis (Fig. 3). A similar mobility to plasma α_1 -protease inhibitor (B) was found for neoplastic (A) and normal (C) ovary when monospecific antiserum against α_1 -protease inhibitor I and II were used.

Functional localization of trypsin inhibitors. Subcellular fractions from normal (A.S.) and malignant (G.B.) ovary were tested for trypsin inhibition using peptide substrate (Bz-Phe-Val-Arg-pNA). Trypsin inhibitory activity was present mainly in the soluble fraction (80% of the total activity). Lysosomal and membrane fractions contained 11.2 and 8.4% of the total activity. About 75% of the antitrypsin activity in the soluble fractions was located in the 50–80% saturation precipitate of ammonium sulfate and the remaining 25% of the activity was in the 25–50% saturation fraction. The homogenate and subcellular fractions of normal and malignant ovaries (80–100 μg total protein) were tested for urokinase inhibition. No inhibitory activity was found. The soluble fractions of normal and malignant ovaries revealed low levels of antiplasmin activity using H-D-Val-Leu-Lys-pNA. This activity is precipitated by ammonium sulfate at 25–50% saturation.

Purification of α_1 -protease inhibitor. Since the major portion of cellular α_1 -protease inhibitor was found in the soluble fraction, this fraction was used as the source for the α_1 -protease inhibitor purification. The normal ovary obtained from B.L. was fractionated as described in Methods. The α_1 -protease inhibitor was localized in soluble and membrane fractions, while the antitrypsin activity was also present in the lysosomes. Similar results were obtained for the tissues of A.S. and G.B. Results of the QAE-Sephadex chromatography on the normal ovary soluble fraction are presented in Fig.

the primary step in staining both normal and neoplastic ovaries. Frame B shows part of a normal ovarian cortex containing intense reaction product in epithelial and stromal cells, $\times 400$. Frame C shows an ovary with carcinoma with no reaction product in the typical tubular structures lined by clear and "hobnail" cells, whereas several cells in the stromal cytoplasm showed positive α_1 -antitrypsin reaction, $\times 400$. Frame D shows at higher magnification serial section of the ovarian carcinoma shown in Frame C. Antigen is present in many stromal cells, $\times 500$. Frame E shows an ovary with carcinoma with numerous cytoplasmic globules in necrotic region. The amount of stored α_1 -antitrypsin in the tumor globules as revealed by the peroxidase-antiperoxidase technique is quite irregular, $\times 400$. Frame F shows an ovary with carcinoma with many tumor cells containing α_1 -antitrypsin $\times 450$.

FIGURE 2 Double immunodiffusion of soluble and membrane fractions of normal and malignant ovaries. Plate a represents normal ovary samples: well 1, 10 μ l soluble fraction; wells 2 and 5, 8 μ l of 1:20 diluted sample of pooled normal plasma. Well 3 contains 20 μ l of soluble fraction, and well 4 15 μ l of the membrane solubilized in Triton X-100. Plate b represents ovarian carcinoma: well 1 20 μ l of soluble fraction; wells 2 and 4, 8 μ l of 1:20 diluted normal pooled plasma; well 3, 20 μ l of membrane solubilized in Triton X-100, well 5, 20 μ l of membrane solubilized with deoxycholate. Center wells contain 7 μ l of α_1 -protease inhibitor antiserum.

4. A single trypsin inhibitory peak as measured against the amide substrate Bz-Phe-Val-Arg-pNA was eluted following the salt gradient, coincident with the α_1 -protease inhibitor antigen peak. Fractions indicated by the bar, containing the inhibitory activity and the α_1 -protease inhibitor antigen were pooled, concentrated, and gel filtered through a Sepharose-4B column (Fig. 5). A single peak of trypsin inhibitor activity that also demon-

strated α_1 -protease inhibitor antigen (not shown) was located in a region corresponding to $\sim 60,000$ mol wt. When fractions were tested for human plasmin inhibition using H-D-Val-Leu-Lys-pNA peptide substrate, a small but distinct inhibitory activity was found under the antitrypsin peak. Alkaline disc gel analysis of the Sepharose-4B peak revealed several contaminating proteins including one with similar mobility to α_1 -glycoprotein. Therefore, this material was further purified by chromatography on DE-52 cellulose at pH 6.5 (37). Results of the chromatography are summarized in Fig. 6. After removal of the unadsorbed proteins, the antitrypsin activity was eluted by applying a linear salt gradient (arrow) up to 0.2 M NaCl. Fractions containing the antitrypsin activity were pooled, concentrated, and dialyzed against 0.01 M Na-acetate buffer at pH 6.5 containing 0.2 M NaCl, 1 mM CaCl_2 , and 1mM MgCl_2 . To remove the major contaminant albumin, the sample was passed through Con A-Sepharose equilibrated with the above acetate buffer (Fig. 7). After complete removal of the unadsorbed proteins by the starting buffer, the α_1 -protease inhibitor was eluted by 0.1 M α -D-methyl-glucoside in a single symmetrical peak corresponding to a discrete protein peak. Similar procedures were applied for the purification of α_1 -protease inhibitor from the ovarian carcinoma. No major differences were noted in the chromatographic patterns compared to normal ovary.

The entire purification is summarized in Table I for both normal and malignant ovaries. On the basis of trypsin inhibitory activity an overall purification of 16-

FIGURE 3 Immunoelectrophoresis of soluble fraction from normal and malignant ovaries. Wells contain the following samples: A, soluble fraction from ovarian carcinoma; B, diluted normal plasma; C, soluble fraction from normal ovary. In each case samples contained ~ 50 μ g of total protein. Troughs I and II contained 60 μ l of α_1 -protease inhibitor antiserum.

FIGURE 4 QAE-Sephadex chromatography of the normal ovary soluble fraction. A total of 60 mg protein was applied onto a 1.6×15 -cm column equilibrated with 0.0035 M phosphate buffer containing 0.06 M NaCl at pH 8.0. As indicated by the arrow a gradient consisting of 150 ml of starting buffer in the mixing chamber and 150 ml of the same buffer containing 0.7 M NaCl in the reservoir was started. 3.3 ml fractions were collected. $\times$ indicate A_{280} ; $\circ$ antitrypsin activity; $\bullet$ α_1 -protease inhibitor antigen.

and 20-fold were obtained from normal and malignant ovaries, respectively. If one calculates the purification on the basis of α_1 -protease inhibitor antigen higher values of 30- and 44-fold were obtained. This apparent discrepancy is because of the inclusion of tryptic inhibitory activity due to other inhibitors distinct from α_1 -protease inhibitor in the starting soluble fraction. The yield for α_1 -protease inhibitor from both normal and malignant ovary, based on the antigen data is $\sim 20\%$.

To demonstrate the homogeneity of the preparation, three criteria were chosen. An alkaline disc gel electrophoresis of highly purified preparation of α_1 -protease inhibitor (Fig. 8) obtained from normal and malignant ovaries revealed a single major protein band. The pro-

FIGURE 5 Sepharose-4B gel filtration. The pooled and concentrated fractions 56-63 (|—|, Fig. 3) from QAE-Sephadex (14 mg total protein) were gel filtered through a 1.6×86.5 cm column equilibrated with 0.01 M Tris-Cl containing 0.13 M NaCl at pH 7.4. Fractions of 1.3 ml were collected. Symbols same as Fig. 4 but in addition Δ represent antiplasma activity.

FIGURE 6 DEAE-cellulose chromatography. Fractions 108-122 (|—|, Fig. 5) from Sepharose-4B were pooled, concentrated and applied (1.25 ml) onto a 1.5×8 -cm column equilibrated with 0.005 M phosphate buffer containing 0.05 M NaCl, pH 6.5. As indicated by the arrow a gradient consisting of 200 ml of the above buffer in the mixing chamber and 200 ml of the same buffer containing 0.2 M NaCl in the reservoir was started. 5-ml fractions were collected. Symbols are the same as Fig. 3.

tein that represents $>90\%$ of the total protein had a mobility similar to α_1 -protease inhibitor. To demonstrate that the major protein band represents the purified α_1 -protease inhibitor, crossed two-dimensional immunoelectrophoresis was performed. A duplicate unstained gel was placed in a 1% agarose containing 1% (vol/vol) α_1 -protease inhibitor antiserum immediately after disc gel electrophoresis and the proteins were subjected to electrophoresis into the second dimension. The rockets formed (Fig. 8) correspond to the region of the gels where the major protein bands migrated. In the normal ovary (Fig. 8A) the rocket was symmetrical, but in the ovarian carcinoma (Fig. 8B) a slower migrating shoulder appeared in front of the main rocket suggesting microheterogeneity. Analysis of the phenotype of the purified α_1 -protease inhibitor revealed a normal (PiMM) pattern for both normal and malignant ovaries. Both the normal and malignant ovaries show a major band on sodium dodecyl sulfate gel electrophoresis corresponding to a molecular weight of 53,500 (Fig. 9).

FIGURE 7 Con-A-Sepharose affinity chromatography. The preparation obtained from DEAE-cellulose (|—|, Fig. 6) was pooled and concentrated and 3 ml were applied onto a 1.5-ml (packed volume) resin in a Pasteur pipette (See text). Elution of the α_1 -protease inhibitor was initiated at the arrow with 0.1 M solution of α -methyl-D-glucoside in tris buffer (Methods). 1-ml fractions were collected with a flow rate of 7-ml/h. Symbols are the same as Fig. 4.

TABLE I
Purification of Ovarian α_1 -Protease Inhibitor

	Protein	Volume	Trypsin inhibitory activity	Specific activity	Purification	α_1 -PI	Specific activity	Purification	Yield
	mg/ml	ml	U/ml	U/mg		μ g/ml	μ g/mg		%
From normal ovary									
Soluble fraction	1.335	45	130	97.4	1	40	30.0	1	100
QAE pool	3.95	4	875	222	2.3	310	78.5	2.62	69
Sepharose-4B pool	2.50	3	780	312	3.2	300	120	4	50
DE-52	—	7.2	—	—	—	—	—	—	—
Con-A Sepharose	0.084	4.30	130	1,550.6	16	76	905	30.2	18.2
From ovarian carcinoma									
Soluble fraction	1.65	25	66.5	40.3	1	30	18.2	1	100
QAE pool	4.25	4.3	266	62.6	1.5	160	37.2	2.1	92
Sepharose-4B pool	3.73	3.55	300	80.5	2	164	44.0	2.42	78
DE-52	—	6.66	—	—	—	—	—	—	—
Con-A Sepharose	0.06	3.55	90	820	20.3	47.6	793	43.6	22.5

All protein determinations were performed by micro Folin method, α_1 -protease inhibitor micrograms per milliliter was determined immunochemically as is the specific activity micrograms per milligram.

Kinetic studies. The inhibition of bovine trypsin by ovarian α_1 -protease inhibitor at various substrate (Bz-Phe-Val-Arg-pNA) concentrations is presented by the Lineweaver-Burk plot in Fig. 10. A competitive inhibi-

tion of trypsin is observed by α_1 -protease inhibitor from normal ovary and ovarian carcinoma. Inhibition constant (K_i) values are calculated at 0.67 and 0.51 U, respectively.

FIGURE 8 Crossed immunoelectrophoresis of purified α_1 -protease inhibitor. Tubes 15–20, Fig. 7 were pooled and concentrated. In the first dimension, α_1 -protease inhibitor obtained from concanavalin A-Sepharose step was applied onto alkaline disc gel (total protein used was 5 μ g for normal ovary (A) and 4.2 μ g for ovarian carcinoma (B)). One gel was stained (presented in the figure). In the second dimension, a duplicate gel was electrophoresed into the antibody containing agarose gel (see text for detail). The plates were stained with Coomassie blue to visualize the immune precipitate (rocket).

FIGURE 9 Sodium dodecyl sulfate gel electrophoresis of the highly purified α_1 -protease inhibitor. Preparations obtained from concanavalin A-Sepharose were used. The total proteins used were 5- μ g for α_1 -protease inhibitor from normal ovary (gel 1) and 4 μ g for α_1 -protease inhibitor from ovarian carcinoma (gel 2).

DISCUSSION

α_1 -Protease inhibitor was identified immunohistochemically in epithelial, stromal and tumor cells of nine ovaries from nine patients by the use of specific anti- α_1 -protease inhibitor antibody and the indirect peroxidase method. The interstitial space in the ovaries was essentially free of reaction product. Protease inhibitor from three ovaries was isolated, purified, and studied for its molecular, antigenic, and inhibitory activity.

Using the soluble fraction of the ovarian cell homogenates as a source of α_1 -protease inhibitor, purification by ion exchange chromatography, gel filtration, and lectin affinity chromatography resulted in a preparation that revealed a singel band on polyacrylamide disc gel electrophoresis in the presence and absence of sodium dodecyl sulfate. Crossed immunoelectrophoresis demonstrated that this protein band was identical to the α_1 -protease inhibitor antigen in plasma. Although α_1 -protease inhibitor from normal and malignant cells were similar in migration, a slower migrating shoulder was evident in the preparations of the α_1 -protease inhibitor from malignant tissue. The similarity to plasma

FIGURE 10 Kinetics of the inhibition of bovine trypsin by α_1 -protease inhibitor from ovarian tissue. In a total of 1 ml vol, 0.25 μ g bovine trypsin was incubated with 0.1 M Tris imidazole buffer at pH 7.4 containing 0.1 M NaCl and 0.5 mg/ml bovine serum albumin ($\times$) or buffer plus 0.53 μ g α_1 -protease inhibitor from malignant ovary ($\bullet$) for 5 min at 30°. Bz-Phe-Val-p NA at various concentrations was added and the residual amidase activity measured (Methods). The Con-A preparations of α_1 -protease inhibitor were used.

α_1 -protease inhibitor is further supported by the finding of a normal phenotype (PiMM). The molecular weight of normal and malignant ovarian α_1 -protease inhibitor as determined by gel filtration (60,000) and sodium dodecyl sulfate-gel electrophoresis (53,500) were in agreement with those reported for α_1 -protease inhibitor from plasma (38, 39) and platelets (33).

Kinetics of trypsin inhibition by highly purified ovarian α_1 -protease inhibitor was competitive in nature similar to the inhibition of trypsin by platelet α_1 -protease inhibitor and renin by plasma α_1 -protease inhibitor (4).

This study clearly established that α_1 -protease activity is present in the cells of normal and malignant ovaries. However, the evidence presented does not distinguish between synthesis by ovarian tissue or endocytosis of α_1 -protease inhibitor by ovarian cells. The presence of α_1 -protease inhibitor in the stromal cells of ovaries may be important in ovulation since stromal cells as well as the epithelial (so-called germinal) cells participate in the maturation of follicles, production of estrogen and formation of the corpus luteum. Although the mechanism of rupture of the mature follicle is not fully understood, proteolytic enzymes may play a role. Plasminogen activator has been shown to be involved in ovula-

tion (40). Other enzymes have been isolated from sea urchin eggs (41) including a homogenous enzyme similar to bovine trypsin in its molecular weight and susceptibility to inhibitors diisopropylfluoro-phosphate and soybean trypsin inhibitor (42). The presence of the α_1 -protease inhibitor in ovarian tissue might serve to prevent extensive autodigestion of the tissue by tryptic enzymes following ovulation.

The number of samples examined in detail in this study was too small to allow comparison of the level of α_1 -protease inhibitor in normal and malignant ovarian cells. However, several studies suggest that inhibitor levels might be important, since increased protease activity is associated with transformation and uncontrolled proliferation (43–46). Cancerous tissues of the bladder contained significantly higher levels of the mammalian cellular protease inhibitors, urokinase inhibitor and tissue plasminogen activator inhibitor than normal mucosa (47). Ascitic fluid from patients with ovarian carcinoma contain much higher levels of trypsin inhibitors compared to ascitic fluid from patients with benign ovarian tumors (48). However, whether any of these inhibitory activities were due to α_1 -protease inhibitor is not known. α_1 -protease inhibitor has been demonstrated by immunofluorescence in sections of tumor tissue in patients with endodermal sinus tumors (49, 50), but a quantitative comparison with comparable normal tissue is not available. α_1 -protease inhibitor is also synthesized by a human hepatoma cell line (51). The presence of relatively high levels of α_1 -protease inhibitor in normal ovarian tissue and in malignant ovaries suggests that this inhibitor may be involved in the regulation of proliferation in normal and malignant tissues.

ACKNOWLEDGMENTS

The authors thank Dr. Richard Talamo of Johns Hopkins School of Medicine for performing the α_1 -protease inhibitor phenotyping and Mr. Charles Uschmann and Ms. Terry Cruice for preparation of the manuscript.

This project was partly supported by Specialized Center of Research grant HL14217 and research grant HL24365.

REFERENCES

1. Wu, F. C., and M. Laskowski. 1960. Crystalline acid-labile trypsin inhibitor from bovine blood plasma. *J. Biol. Chem.* **235**: 1680–1685.
2. Turino, G. M., R. M. Senior, B. D. Garg, et al. 1969. Serum elastase inhibitor deficiency and α_1 -antitrypsin deficiency in patients with obstructive emphysema. *Science (Wash. D. C.)* **165**: 709–711.
3. Eisen, A. Z., K. J. Bloch, and T. S. Sakai. 1970. Inhibition of human skin collagenase by human serum. *J. Lab. Clin. Med.* **75**: 258–263.
4. Scharpe, S., M. Eid, W. Cooperman, and A. Lauwers. 1976. α_1 -Antitrypsin, an inhibitor of renin. *Biochem. J.* **153**: 505–507.
5. Erickson, S. 1965. Studies in α_1 -antitrypsin deficiency. *Acta Med. Scand. (Suppl. 177)* **432**: 1–85.
6. Lieberman, J. 1969. Heterozygous and homozygous Alpha₁-antitrypsin deficiency in patients with pulmonary emphysema. *N. Engl. J. Med.* **281**: 279–284.
7. Sharp, H. L., R. A. Bridges, W. Kruit, and F. Freier. 1969. Cirrhosis associated with alpha-1-antitrypsin deficiency: a previously unrecognized inherited disorder. *J. Lab. Clin. Med.* **73**: 934–939.
8. Talamo, R. C., J. B. Blennerhassett, and K. F. Austen. 1966. Familial emphysema and alpha₁-antitrypsin deficiency. *N. Engl. J. Med.* **275**: 1301–1304.
9. Sharp, H. L. 1971. Alpha-1-antitrypsin deficiency. *Hosp. Pract.* **6** (5): 83–96.
10. Rowley, P. T., and L. L. Miller. 1975. Serum antitrypsin synthesis by the isolated perfused rat liver. *Proc. Soc. Exp. Biol. Med.* **148**: 145–150.
11. Bhan, A. K., R. J. Grand, H. R. Colten, and C. A. Alper. 1976. Liver in α_1 -antitrypsin deficiency: morphologic observations and in vitro synthesis of α_1 -antitrypsin. *Pediatr. Res.* **10**: 35–40.
12. Koj, A., E. Regoeczi, C. J. Toews, R. Leveille, and J. Gauldie. 1978. Synthesis of antithrombin III and alpha-1-antitrypsin by the perfused rat liver. *Biochim. Biophys. Acta.* **539**: 496–504.
13. Schnebil, H. B. 1974. Growth inhibition of tumor cells by protease inhibitors: consideration of the mechanism involved. *Cold Spring Harbor Conf. Cell Proliferation.* **1**: 327–337.
14. Verloes, R., G. Atassi, P. Dumont, and L. Kananek. 1978. Tumor growth inhibition mediated by trypsin inhibitor or urokinase inhibitors. *Eur. J. Cancer.* **14**: 23–31.
15. Moreau, P., J. Dornand, and J. G. Kaplan. 1975. Inhibition of lymphocyte transformation: effect of soybean trypsin inhibitor and synthetic anti-proteases. *Can. J. Biochem.* **53**: 1337–1341.
16. Schnebil, H. P., and M. M. Burger. 1972. Selective inhibition of growth of transformed cells by protease inhibitors. *Proc. Natl. Acad. Sci. U. S. A.* **69**: 3825–3827.
17. Bosmann, H. B. 1972. Elevated glycosidases and proteolytic enzymes in cells transformed in RNA tumor virus. *Biochim. Biophys. Acta.* **264**: 339–343.
18. Beers, W. H., S. Strickland, and E. Reich. 1975. Ovarian plasminogen activator: relationship to ovulation and hormonal regulation. *Cell.* **6**: 387–394.
19. Sternberger, L. A., P. A. Hardy, Jr., J. J. Cwiudis, and H. G. Meyer. 1970. The unlabeled antibody enzyme method of immunohistochemistry. Preparation and properties of soluble antigen-antibody (horseradish peroxidase-antihorseradish peroxidase) and its use in identification of spirochets. *J. Histochem. Cytochem.* **18**: 315–333.
20. Pearse, A. G. E. 1972. Histochemistry: theoretical and applied. 3rd edition. Oxidoreductases I (Oxidases and Peroxidases). The Williams & Williams Company, Baltimore **2**: 850–857.
21. Ouchterlony, O. 1953. Antigen-antibody reactions in gels. IV. Types of reactions in coordinated systems of diffusion. *Acta Pathol. Microbiol. Scand.* **32**: 230–240.
22. Deutsch, D. G., and E. T. Mertz. 1970. Purification from human plasma by affinity chromatography. *Science (Wash. D. C.)* **170**: 1095–1096.
23. Colman, R. W., and A. Bagdasarian. 1976. Human kallikrein and prekallikrein. *Methods Enzymol.* **45**: 303–322.
24. Davis, B. J. 1964. Disc electrophoresis-II Method and application to human serum proteins. *Ann. N. Y. Acad. Sci.* **121**: 404–427.
25. Weber, K., and M. Osborn. 1969. The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. *J. Biol. Chem.* **244**: 4406–4412.

26. Murray, R. K., R. Suss, and H. C. Pitot. 1967. Isolation and Characterization of cytoplasmic components of cancer cells. *Methods Cancer Res.* 2: 239-286.
27. Swanti, P. L., S. Shibko, N. S. Kumata, and A. L. Tappel. 1964. Isolation of rat-liver lysosomes and their general properties. *Biochim. Biophys. Acta.* 85: 82-92.
28. Mancini, G., A. O. Carbonaro, and J. F. Heremans. 1965. Immunochemical quantitation of antigens by single radial immunodiffusion. *Immunochemistry.* 2: 235-254.
29. Scheidegger, J. J. 1955. Une micro-méthode de l'immuno-électrophorèse. *Int. Arch. Allergy Appl. Immunol.* 7: 103-110.
30. Laurell, C. B. 1965. Antigen-antibody crossed electrophoresis. *Anal. Biochem.* 10: 358-361.
31. Fagerhol, M. K., and C. B. Laurell. 1967. Polymorphism of "Prealbumins" and α_1 -antitrypsin in human sera. *Clin. Chim. Acta.* 16: 199-203.
32. Cuatrecasas, P. 1970. Protein purification by affinity chromatography. *J. Biol. Chem.* 245: 3059-3065.
33. Bagdasarian, A., and R. W. Colman. 1978. Subcellular localization and purification of platelet α_1 -antitrypsin. *Blood.* 51: 139-156.
34. Chase, T., and E. Shaw. 1967. p-Nitrophenyl-p-guanidinobenzoate HCL: a new active titrant for trypsin. *Biochem. Biophys. Res. Commun.* 29, 508-514.
35. Alkjaersig, N., A. P. Fletcher, and S. Sherry. 1959. E-Aminocaproic acid: an inhibitor of plasminogen activation. *J. Biol. Chem.* 234: 832-837.
36. Casati, P., M. Grandi, and N. Toccaceli. 1975. Urinary trypsin-inhibitor: extraction from pregnancy urine by affinity chromatography. *Ital. J. Biochem (Engl. Ed.)* 24: 188-198.
37. Pannell, R., D. Johnson, and J. Travis. 1974. Isolation and properties of human plasma α_1 -proteinase. *Biochemistry.* 13: 5439-5444.
38. Crawford, I. P. 1973. Purification and properties of normal human α_1 -antitrypsin. *Arch. Biochem. Biophys.* 156: 215-222.
39. Glaser, C. B., L. Karic, and R. Fallat. 1975. Isolation and characterization of alpha-1-antitrypsin from the Cohn Fraction IV-I of human plasma. *Prep. Biochem.* 5: 333-348.
40. Strickland, S. and W. H. Beers. 1976. Studies on the role of plasminogen activator in ovulation. *J. Biol. Chem.* 251: 5694-5702.
41. Carroll, E. J. 1976. Cortical granule proteases from sea urchin eggs. *Methods Enzymol* 45: 343-353.
42. Fodor, E. J., H. Ako, and K. A. Walsh. 1975. Isolation of a protease from sea urchin eggs before and after fertilization. *Biochemistry.* 14: 4923-4927.
43. Reich, E. 1975. Plasminogen activators: secretion by neoplastic cells and macrophages. In *Protease and Biological Control. Cold Spring Harbor Conf. Cell Proliferation.* 2: 333-341.
44. Roblin, R., C. Iih-Nan, and P. H. Blach. 1975. Proteolytic enzymes, cell surface changes, and viral transformation. *Adv. Cancer Res.* 22: 203-259.
45. Burger, M. D. 1970. Release from density dependent growth inhibition by proteolytic enzymes. *Nature (Lond.).* 227: 843-845.
46. Sefton, B. M., and H. Rubin. 1970. Release from density dependent growth inhibition by proteolytic enzymes. *Nature (Lond.).* 227: 843-845.
47. Hisazumi, H. 1973. Inhibitory effect of normal and cancerous tissues of the bladder on plasminogen activation. *Invest. Urology.* 11: 258-262.
48. Svandberg, L., and B. Astedt. 1975. Coagulative and fibrinolytic properties of ascitic fluid associated with ovarian tumors. *Cancer (Phila.).* 35: 1382-1387.
49. Palmer, P. E., H. Safaii, and J. J. Wolfe. 1976. Alpha₁-antitrypsin and alpha-fetoprotein. *Amer. J. Clin. Pathol.* 65: 575-582.
50. Shirai, T., T. Itoh, and T. Yoshiki. 1976. Immunofluorescent demonstration of alpha-fetoprotein and other plasma proteins in yolk sac tumor. *Cancer (Phila.).* 38: 1661-1667.
51. Glasgow, J., A. Bagdasarian, and R. W. Colman. 1978. Alpha-1-antitrypsin produced by a human hepatoma cell line. *Fed. Prod.* 37: 1337. (Abstr.)